FDA proposes $22 million in user fees

02/20/2006 | Boston Globe (tiered subscription model), The

The FDA has requested that Congress approve $22 million in new user fees to be paid by medical device and drug companies whose facilities require reinspection by the agency. Although the policy might encourage companies to clean up FDA violations in their plants more quickly, the reinspection fees could mean significant costs for the companies.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Paralegal, Legal-Regulatory
Confidential
Piscataway, NJ